DDInter610 DDInter1676
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tumour cells.[L12621,L12627] Durvalumab is marketed under the brand name Imfinzi, which is available for intravenous injections. It was granted accelerated approval by the FDA in May 2017 for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma. In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in ≥ 1%
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Durvalumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Durvalumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Durvalumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Durvalumab {u} may lead to a major life threatening interaction when taken with {v} Tofacitinib
Durvalumab {u} may lead to a major life threatening interaction when taken with {v} Baricitinib
Durvalumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Durvalumab may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone
Durvalumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Durvalumab may lead to a major life threatening interaction when taken with Tofacitinib
Durvalumab may lead to a major life threatening interaction when taken with Baricitinib